Vineet Laboratories Ltd
NSE:VINEETLAB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/FCFF
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Valuation Scenarios
If EV/FCFF returns to its 3-Year Average (12.7), the stock would be worth ₹33.42 (13% downside from current price).
| Scenario | EV/FCFF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 14.7 | ₹38.55 |
0%
|
| 3-Year Average | 12.7 | ₹33.42 |
-13%
|
| 5-Year Average | 11.5 | ₹30.19 |
-22%
|
| Industry Average | 47.3 | ₹124.1 |
+222%
|
| Country Average | 35.9 | ₹94.12 |
+144%
|
Forward EV/FCFF
Today’s price vs future free cash flow to firm
Peer Comparison
| Market Cap | EV/FCFF | P/E | ||||
|---|---|---|---|---|---|---|
| IN |
|
Vineet Laboratories Ltd
NSE:VINEETLAB
|
740.5m INR | 14.7 | -7.3 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
804.2B USD | 140.4 | 39 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
547.4B USD | 29.1 | 26 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 26.4 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
212.4B GBP | 35.6 | 28.2 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
274.6B USD | 24.8 | 15 | |
| CH |
|
Novartis AG
SIX:NOVN
|
216.3B CHF | 19.5 | 20.6 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 1 486.8 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 43.7 | 11.5 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
149.3B USD | 21.8 | 19.2 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
115.9B USD | 11.6 | 16.4 |
Market Distribution
| Min | 0.1 |
| 30th Percentile | 20.7 |
| Median | 35.9 |
| 70th Percentile | 64.8 |
| Max | 50 585.9 |
Other Multiples
Vineet Laboratories Ltd
Glance View
Vineet Laboratories Ltd. specializes in pharmaceutical intermediates and fine chemicals. The company is headquartered in Hyderabad, Telangana. The company went IPO on 2021-06-15. The firm is specialized in manufacturing pharmaceutical intermediates and fine chemicals. The firm is also specialized in manufacturing and handling pyrophoric chemicals like n-Butyl Lithium, Isopropyl-beta-D-thiogalactopyranoside (IPTG), 4-Nitrophenyl phosphate disodium salt (PNPP), 4-Chlorobutyryl chloride, n-Butyl magnesium chloride, 3-Furaldehyde, 3-bromofuran, n-Butylnitrite, Ethyldiazo acetate, Phenylboronic acid, Dimethyl phenoxy acetyl chloride and Piroctone Olamine.
